REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Sucrose is used in prepared foods (e.g., cookies and cakes), is added to commercially available ultra-processed food and beverages, and is used as a sweetener for foods (e.g., toast and cereal) and beverages (e.g., coffee and tea). Globally, on average, a person consumes about 24 kilograms (53 pounds) of sugar each year. North and South Americans consume up to 50 kg (110 lb), and Africans consume under 20 kg (44 lb). The use of added sugar in food and beverage manufacturing is a concern for elevated calorie intake, which is associated with an increased risk of several diseases, such as obesity, diabetes and cardiovascular disorders. In 2015 the World Health Organization recommended that adults and children should reduce their intake of free sugars to less than 10% of their total energy intake, encouraging a reduction to below 5%.
=== Build === Though Neanderthals are often imagined as short and stocky, they were on average the same height as pre-industrial Europeans, or even slightly taller. The body mass index of the average European Neanderthal was comparable to 20th century Canadians and Americans. Neanderthal body size varied by location; West Asian Neanderthals were taller and more slightly built than European Neanderthals. In a sample of 45 Neanderthal long bones from 14 men and 7 women, the average height was 164 to 168 cm (5 ft 5 in to 5 ft 6 in) for males and 152 to 156 cm (5 ft 0 in to 5 ft 1 in) for females. The fossil record shows that adult Neanderthals varied from about 147.5 to 177 cm (4 ft 10 in to 5 ft 10 in) in height. The average male body mass index was 26.9–28.3. Neanderthal pelvic bones were extremely wide; with Neanderthal male hips being approximately 31% wider than those of modern humans males. As in all archaic species, there is no evidence of sexual dimorphism in the Neanderthal pelvis; both males and females had large pelvic bones relative to their body size, with larger males having the largest pelvises. The Neanderthal chest was deep and wide, with a proportionally expansive thoracic cavity, and possibly stronger lung performance. and much higher caloric demands. The limbs are proportionally short. The body plan has traditionally been explained as a "hyper-arctic" adaptation (Allen's rule). Neanderthals would also have been effective sprinters: stronger lungs, and shorter limbs would have boosted efficiency.
== History == Guzman y Gomez was established by Steven Marks, a New Yorker who previously worked as a hedge fund manager. After relocating to Australia, he found the quality of Mexican food to be poor and decided to start a restaurant. He has stated that "real Mexican is really urban, street and hot [...] Latin people are so full of energy and full of life, we wanted to bring that to Australia". He took on his friend Robert Hazan, another New Yorker, as a partner. They named the business after two of Marks' childhood friends. The first store was opened in King Street, Newtown, Sydney, in 2006. Store openings in Bondi Junction and Kings Cross, followed within a year. By April 2012, there were 12 stores. The first Guzman y Gomez in the Melbourne central business district opened in November 2012. Within 12 years, they opened 100 stores in Australia. The first international Guzman y Gomez restaurant opened at the end of 2013 in Singapore, followed thereafter by the opening of a restaurant in Tokyo, Japan, in April 2015. In January 2020, Guzman y Gomez's international expansion continued with the opening of their first restaurant in the United States in the Chicago suburb of Naperville. In May 2026, Guzman y Gomez announced the closure of all of their restaurants in the United States.
In 1800, France built Nautilus, a human-powered submarine designed by American Robert Fulton. They gave up on the experiment in 1804, as did the British, when they reconsidered Fulton's submarine design. In 1850, Wilhelm Bauer's Brandtaucher was built in Germany. It remains the oldest known surviving submarine in the world. In 1864, late in the American Civil War, the Confederate navy's H. L. Hunley became the first military submarine to sink an enemy vessel, the Union sloop-of-war USS Housatonic, using a gun-powder-filled keg on a spar as a torpedo charge. The Hunley also sank. The explosion's shock waves may have killed its crew instantly, preventing them from pumping the bilge or propelling the submarine. In 1866, Sub Marine Explorer was the first submarine to successfully dive, cruise underwater, and resurface under the crew's control. The design by German American Julius H. Kroehl (in German, Kröhl) incorporated elements that are still used in modern submarines. In 1866, Flach was built at the Chilean government's request by Karl Flach, a German engineer and immigrant. It was the fifth submarine built in the world and, along with a second submarine, was intended to defend the port of Valparaíso against attack by the Spanish Navy during the Chincha Islands War.
Sources: en.wikipedia.org
== Interactions == LRP5 has been shown to interact with AXIN1. Canonical WNT signals are transduced through Frizzled receptor and LRP5/LRP6 coreceptor to downregulate GSK3beta (GSK3B) activity not depending on Ser-9 phosphorylation. Reduction of canonical Wnt signals upon depletion of LRP5 and LRP6 results in p120-catenin degradation.
Repeated bombing of Bremen in World War II resulted in the mass-production plants being moved to eastern Germany and General Government, with AGO Flugzeugwerke of Oschersleben as a major subcontractor for the Fw 190. Those plants used many foreign and forced labourers, and from 1944 also prisoners of war. Focke-Wulf's 100-acre (0.40 km2) plant at Marienburg produced approximately half of all Fw 190s and was bombed by the Eighth Air Force on 9 October 1943. Many Focke-Wulf workers, including Kurt Tank, worked at the Instituto Aerotécnico in Córdoba, Argentina between 1947 and 1955. Others, like Henrich Focke, went to Brazil's Department of Aerospace Science and Technology, helping Brazil's effort to build Embraer. Focke-Wulf began to make gliders in 1951, and in 1955, motorised planes. Focke-Wulf, Weserflug and Hamburger Flugzeugbau joined forces in 1961 to form the Entwicklungsring Nord (ERNO) to develop rockets. ITT Corporation, which had acquired a 25% stake in the company prior to the war, won $27 million in compensation in the 1960s for the damage that was inflicted on its share of the Focke-Wulf plant by WWII Allied bombing. Colonel Sosthenes Behn, Ludwig Roselius and Barbara Goette outfoxed Hitler in 1936 when he tried to have Roselius removed as a major stakeholder from Focke-Wulf A.G. and reconstitution followed resulting in the privatized company Focke-Wulf Flugzeugbau GmbH.
In the United States, it was once widely used as a food additive in root beer, sassafras tea, and other common goods, but was banned for human consumption by the FDA after studies in the 1960s suggested that safrole was carcinogenic, causing permanent liver damage in rats; food products sold there purporting to contain sassafras instead contain a safrole-free sassafras extract. Safrole is also banned for use in soap and perfumes by the International Fragrance Association. According to a 1977 study of the metabolites of safrole in both rats and humans, two carcinogenic metabolites of safrole found in the urine of rats, 1′-hydroxysafrole and 3′-hydroxyisosafrole, were not found in human urine. The European Commission on Health and consumer protection assumes safrole to be genotoxic and carcinogenic. It occurs naturally in a variety of spices, such as cinnamon, nutmeg, and black pepper, and herbs such as basil. In that role, safrole, like many naturally occurring compounds, may have a small but measurable ability to induce cancer in rodents. Despite this, the effects in humans were estimated by the Lawrence Berkeley National Laboratory to be similar to risks posed by breathing indoor air or drinking municipally supplied water.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.